ResMed Inc (RMD)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $33.69B
Last updated: Nov 17, 2026 at 11:06 AM ET
ResMed Inc (RMD) Earnings: Report Dates and Results
ResMed (RMD) is expected to report earnings on Jan 27, 2027. In the quarter ended Sep 30, 2026, ResMed reported EPS of $2.91, above the $2.67 estimate. It beat the EPS estimate in each of the last 13 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RMD has an expected report date of Jan 27, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 6.4% above the $2.81 reported for the quarter ended Dec 31, 2025.
RMD Earnings Call
The latest RMD earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, RMD beat 35, missed 4 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $1.41B, up 5.2% from $1.34B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $2.91 | $2.67 | $2.62 - $2.76 | +8.99% | Beat | +14.1% | 13 | 0 up, 1 down | Oct 29, 2026 | $1.41B |
| Jun 30, 2026 | $2.95 | $2.90 | $2.78 - $2.98 | +1.72% | Beat | +15.7% | 9 | 0 up, 1 down | Aug 6, 2026 | $1.46B |
| Mar 31, 2026 | $2.86 | $2.80 | $2.72 - $2.85 | +2.14% | Beat | +20.7% | 13 | 1 up, 2 down | Apr 30, 2026 | $1.43B |
| Dec 31, 2025 | $2.81 | $2.72 | $2.63 - $2.87 | +3.31% | Beat | +15.6% | 14 | 1 up, 0 down | Jan 29, 2026 | $1.42B |
| Sep 30, 2025 | $2.55 | $2.50 | $2.45 - $2.56 | +2.00% | Beat | +15.9% | 12 | 0 up, 0 down | Oct 30, 2025 | $1.34B |
| Jun 30, 2025 | $2.55 | $2.48 | $2.35 - $2.60 | +2.82% | Beat | +22.6% | 13 | N/A | Jul 31, 2025 | $1.35B |
| Mar 31, 2025 | $2.37 | $2.36 | $2.32 - $2.41 | +0.42% | Beat | +11.3% | 12 | 3 up, 6 down | Apr 23, 2025 | $1.29B |
| Dec 31, 2024 | $2.43 | $2.31 | $2.26 - $2.38 | +5.19% | Beat | +29.3% | 13 | 0 up, 1 down | Jan 30, 2025 | $1.28B |
| Sep 30, 2024 | $2.20 | $2.04 | $1.99 - $2.12 | +7.84% | Beat | +34.1% | 8 | 1 up, 0 down | Oct 24, 2024 | $1.22B |
| Jun 30, 2024 | $2.08 | $2.07 | $1.95 - $2.18 | +0.48% | Beat | +30.0% | 11 | 0 up, 0 down | Aug 1, 2024 | $1.22B |
| Mar 31, 2024 | $2.13 | $1.91 | $1.81 - $1.99 | +11.52% | Beat | +26.8% | 10 | 1 up, 0 down | Apr 25, 2024 | $1.20B |
| Dec 31, 2023 | $1.88 | $1.78 | $1.68 - $1.90 | +5.62% | Beat | +13.3% | 9 | 1 up, 0 down | Jan 24, 2024 | $1.16B |
| Sep 30, 2023 | $1.64 | $1.61 | $1.55 - $1.68 | +1.86% | Beat | +8.6% | 9 | 0 up, 2 down | Oct 26, 2023 | $1.10B |
| Jun 30, 2023 | $1.60 | $1.69 | $1.60 - $1.73 | -5.33% | Miss | +7.4% | 10 | 0 up, 1 down | Aug 3, 2023 | $1.12B |
| Mar 31, 2023 | $1.68 | $1.59 | $1.53 - $1.65 | +5.66% | Beat | +27.3% | 9 | 1 up, 1 down | Apr 27, 2023 | $1.12B |
| Dec 31, 2022 | $1.66 | $1.62 | $1.57 - $1.72 | +2.47% | Beat | +12.9% | 9 | 0 up, 0 down | Jan 26, 2023 | $1.03B |
| Sep 30, 2022 | $1.51 | $1.60 | N/A | -5.63% | Miss | 0.0% | 6 | 0 up, 0 down | Oct 27, 2022 | $950.29M |
| Jun 30, 2022 | $1.49 | $1.46 | N/A | +2.05% | Beat | +10.4% | N/A | 0 up, 0 down | Aug 11, 2022 | $914.74M |
| Mar 31, 2022 | $1.32 | $1.44 | $1.39 - $1.47 | -8.33% | Miss | +1.5% | 6 | 0 up, 0 down | Apr 28, 2022 | $864.50M |
| Dec 31, 2021 | $1.47 | $1.52 | $1.42 - $1.60 | -3.29% | Miss | +4.3% | 5 | 1 up, 0 down | Jan 27, 2022 | $894.87M |
| Sep 30, 2021 | $1.51 | $1.35 | $1.24 - $1.52 | +11.85% | Beat | +18.9% | 6 | 3 up, 0 down | Oct 28, 2021 | $904.01M |
| Jun 30, 2021 | $1.35 | $1.29 | $1.24 - $1.46 | +4.65% | Beat | +1.5% | 8 | N/A | Aug 5, 2021 | $876.10M |
| Mar 31, 2021 | $1.30 | $1.27 | $1.08 - $1.38 | +2.36% | Beat | +0.8% | 8 | N/A | Apr 29, 2021 | $768.77M |
| Dec 31, 2020 | $1.41 | $1.28 | $1.18 - $1.37 | +10.16% | Beat | +16.5% | 8 | N/A | Jan 28, 2021 | $800.01M |
| Sep 30, 2020 | $1.27 | $1.03 | $0.93 - $1.17 | +23.30% | Beat | +36.6% | 8 | N/A | Oct 29, 2020 | $751.94M |
| Jun 30, 2020 | $1.33 | $1.07 | $0.75 - $1.33 | +24.30% | Beat | +40.0% | 8 | N/A | Aug 5, 2020 | $770.35M |
| Mar 31, 2020 | $1.29 | $1.08 | $0.87 - $1.17 | +19.44% | Beat | +44.9% | 8 | N/A | Apr 30, 2020 | $769.46M |
| Dec 31, 2019 | $1.21 | $1.02 | $0.96 - $1.08 | +18.63% | Beat | +21.0% | 8 | N/A | Jan 30, 2020 | $736.16M |
| Sep 30, 2019 | $0.93 | $0.87 | $0.76 - $0.98 | +6.90% | Beat | +14.8% | 7 | N/A | Oct 24, 2019 | $681.06M |
| Jun 30, 2019 | $0.95 | $0.92 | $0.88 - $1.03 | +3.26% | Beat | 0.0% | 7 | N/A | Jul 25, 2019 | $704.94M |
| Mar 31, 2019 | $0.89 | $0.85 | $0.79 - $0.95 | +4.71% | Beat | -3.3% | 8 | N/A | May 2, 2019 | $662.23M |
| Dec 31, 2018 | $1.00 | $0.95 | $0.89 - $0.97 | +5.26% | Beat | 0.0% | 7 | N/A | Jan 24, 2019 | $651.10M |
| Sep 30, 2018 | $0.81 | $0.79 | $0.74 - $0.83 | +2.53% | Beat | +22.7% | 8 | N/A | Oct 25, 2018 | $588.30M |
| Jun 30, 2018 | $0.95 | $0.93 | $0.89 - $1.00 | +2.15% | Beat | +23.4% | 8 | N/A | Aug 2, 2018 | $623.63M |
| Mar 31, 2018 | $0.92 | $0.86 | $0.79 - $0.91 | +6.98% | Beat | +29.6% | 6 | N/A | Apr 26, 2018 | $591.63M |
| Dec 31, 2017 | $1.00 | $0.78 | $0.75 - $0.81 | +28.21% | Beat | +37.0% | 7 | N/A | Jan 22, 2018 | $601.27M |
| Sep 30, 2017 | $0.66 | $0.66 | $0.63 - $0.69 | 0.00% | In line | +6.5% | 7 | N/A | Oct 26, 2017 | $523.66M |
| Jun 30, 2017 | $0.77 | $0.74 | $0.70 - $0.78 | +4.05% | Beat | +4.1% | 9 | N/A | Aug 1, 2017 | $556.69M |
| Mar 31, 2017 | $0.71 | $0.70 | N/A | +1.43% | Beat | +4.4% | N/A | N/A | Apr 27, 2017 | $514.20M |
| Dec 31, 2016 | $0.73 | $0.70 | N/A | +4.29% | Beat | +5.8% | N/A | N/A | Jan 23, 2017 | $530.40M |
Annual EPS
EPS for the fiscal year ended Jun 30, 2026 was $11.17, up 17.0% from the year before. It was $2.83 for the year ended Jun 30, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Jun 30, 2026 | $11.17 | +17.0% |
| Jun 30, 2025 | $9.55 | +23.5% |
| Jun 30, 2024 | $7.73 | +19.8% |
| Jun 30, 2023 | $6.45 | +11.4% |
| Jun 30, 2022 | $5.79 | +8.6% |
| Jun 30, 2021 | $5.33 | +12.0% |
| Jun 30, 2020 | $4.76 | +30.4% |
| Jun 30, 2019 | $3.65 | +3.4% |
| Jun 30, 2018 | $3.53 | +24.7% |
| Jun 30, 2017 | $2.83 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,800 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,806 | 14 | |
| 2026Q2 | Jun 30, 2026 | 6,800 | 10 | |
| 2026Q1 | Mar 31, 2026 | 7,589 | 13 | |
| 2025Q4 | Dec 31, 2025 | 6,574 | 12 | |
| 2025Q3 | Sep 30, 2025 | 8,920 | 13 | |
| 2025Q2 | Jun 30, 2025 | 8,009 | 14 | |
| 2025Q1 | Mar 31, 2025 | 9,836 | 17 | |
| 2024Q4 | Dec 31, 2024 | 8,806 | 15 |
2026Q3 Earnings Call
Opening remarks
Sally Schwartz Chief Investor Relations Officer I want to welcome our listeners to ResMed Inc.'s third quarter fiscal year 2026 Earnings Call. We are live webcasting this call and the replay will be available on the Investor Relations section of our corporate website later today. Our earnings press release and presentation are both available online now. During today's call, we will discuss several non-GAAP measures we believe provide useful information for investors. This information is not intended to be considered in isolation or as a substitute for GAAP financial information. We encourage you to review the supporting schedules in today's earnings press release to reconcile these non-GAAP measures with the GAAP reported numbers. In addition, our discussion today will include forward-looking statements including, but not limited to, expectations about our future financial and operating performance. We make these statements based on reasonable assumptions; however, our actual results could differ. Please review our SEC filings for a complete discussion of risk factors that could cause our actual results to differ materially from any forward-looking statements made today. I will now turn the call over to Michael J. Farrell.
Michael J. Farrell Chief Executive Officer (CEO) Thank you, Sally. Before we get into the details discussing our results for the quarter, I am sure all of you have had an opportunity to see our press release and our announcement that Brett will be retiring, and Aaron Blumer has been appointed our next chief financial officer here at ResMed Inc. On behalf of our ResMed Inc. Board and over 10 thousand ResMedians in 140 countries, I would like to thank Brett, who I have had the privilege to partner with for 26 years, including the last 55 quarters as a CEO and CFO team. Brett has been an integral part of my executive team that has delivered growth, expanded access, and improved hundreds of millions of lives. Over two decades as ResMed Inc.'s CFO, Brett has built a financial foundation that has allowed us to deliver strong growth, robust free cash flow, and best-in-class operating margins. Brett has also helped shape the company's culture, and his legacy is embedded in our impact on the lives of many millions of patients worldwide. Brett leaves ResMed Inc. in a position of strength with a very disciplined and global financial team. I am tremendously grateful to Brett for his service, his leadership, his friendship, and his commitment to ResMed Inc. I would also like to welcome Aaron Blumer to ResMed Inc. Aaron brings more than 17 years of global financial leadership, most recently serving as the CFO of Exact Sciences. He has a strong track record of driving strategic growth, operational excellence, and financial discipline across complex global organizations, including prior financial leadership roles at 3M and at Baxter.
Frequently Asked Questions About RMD
When is ResMed's next earnings date?
ResMed's next earnings report is expected for Jan 27, 2027.
Did RMD beat earnings estimates last quarter?
Yes. ResMed reported EPS of $2.91 for the quarter ended Sep 30, 2026, above the $2.67 estimate, a 8.99% surprise.
What EPS do analysts expect from RMD next quarter?
The consensus EPS estimate for ResMed for the quarter ending Dec 31, 2026 is $2.99 from 13 analysts, with estimates from $2.93 to $3.13.
How often does RMD beat earnings estimates?
ResMed beat the EPS estimate in each of the last 13 quarters, with an average surprise of +4.15%.
RMD pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors